Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 3/20 | 1.00 |
| ▸ | TUBB | P07437 | 3/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 3/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 3/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 3/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 3/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 3/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nocodazole SCHEMBL29573963 | 1.00 | ABL1 (1.00) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL9477 | 0.91 | ABL1 (0.84) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL8009081 | 0.91 | ABL1 (0.84) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL29360101 | 0.91 | ABL1 (0.84) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL7615542 | 0.90 | ABL1 (0.82) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL24209744 | 0.89 | ABL1 (0.81) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4557188 | 0.87 | ABL1 (0.78) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL8195415 | 0.87 | ABL1 (0.77) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL8198291 | 0.87 | ABL1 (0.77) | ABL1TUBB4ATUBBTUBA3CTUBA1B | |
| Nocodazole SCHEMBL22418403 | 0.86 | ABL1 (0.76) | ABL1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246014-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SENSID GMBH (DE) | 2024-12-05 | — | — | WO | claimed |
| EP-4467659-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS | SensID GmbH (DE) | 2024-11-27 | — | — | EP | claimed |
| EP-4720329-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SensID GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246014-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS HAVING A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSTIC METHOD | SENSID GMBH (DE) | 2024-12-05 | — | — | WO | disclosed |
| EP-4467659-A1 | REFERENCE MATERIAL COMPRISING NUCLEIC ACIDS WITH A FRAGMENTATION AND NUCLEOSOME PROFILE AND DIAGNOSIS | SensID GmbH (DE) | 2024-11-27 | — | — | EP | disclosed |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-08-24 | — | — | US | disclosed |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2023-08-03 | — | — | US | disclosed |
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | UNIVERSITY OF WASHINGTON (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220017471-A1 | FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS | UNIV SHANGHAI TECHNOLOGY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-6344207-B1 | CLOTHING | TORAY INDUSTRIES, INC. (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-1045065-A1 | Cellulose fiber-containing structure | TORAY INDUSTRIES, INC. (JP) | 2000-10-18 | — | — | EP | disclosed |
| US-5985795-A | CONTAINS INORGANIC METAL ANTIMICROBIAL AGENT, THIAZOLE ANTIMICROBIAL AGENT, HALOALKYLTHIO ANTIMICROBIAL AGENT, IMIDAZOLE ANTIMICROBIAL AGENT, AND UREA ANTIMICROBIAL AGENT | Suganuma, Akio (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0952248-A2 | A molded antimicrobial article and a process for its production | TORAY INDUSTRIES, INC. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0834253-A2 | Antimicrobial composition | Suganuma, Akio (JP) | 1998-04-08 | — | — | EP | disclosed |
| EP-0024842-B1 | METHYL (5-(2-THIENYLHYDROXYMETHYL)-1H-BENZIMIDAZOL-2-YL) CARBAMATE, PROCESS FOR ITS PREPARATION AND COMPOSITIONS CONTAINING IT | SMITHKLINE BECKMAN CORPORATION (US) | 1983-10-05 | — | — | EP | disclosed |
| US-4321393-A | Method for preparing 2-cyanamidobenzimidazoles or 2-cyanamidobenzoxazoles | SMITHKLINE CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
| US-4285878-A | N-Phenyl-N'-cyano-O-phenylisoureas | SMITHKLINE CORPORATION (US) | 1981-08-25 | — | — | US | disclosed |
| EP-0024842-A1 | Methyl (5-(2-thienylhydroxymethyl)-1H-benzimidazol-2-yl) carbamate, process for its preparation and compositions containing it | SMITHKLINE BECKMAN CORPORATION (US) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | ABL1 784/4885TUBB4A 20/4885TUBB 4/4885 |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | PLK2, PLK4, PLK1 | ABL1 1690/4885TUBB4A 11/4885TUBB 6/4885 |
| US-20220017471-A1 | FUNCTIONALITY INDEPENDENT LABELING OF ORGANIC COMPOUNDS | PAICS, PFAS, OTC | ABL1 841/4885TUBB4A 622/4885TUBB 651/4885 |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBA1C, TUBB3, TUBB | ABL1 3163/4885TUBB4A 6/4885TUBB 3/4885 |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | TUBB3, TUBB1, TUBA1C | ABL1 784/4885TUBB4A 20/4885TUBB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.